Age-related macular degeneration (AMD) is a major cause of blindness in the Western World. While only 10% of AMD patients have the exudative form of the.disease, 88% of legal blindness, attributable to AMD, is due to this type. 1 This exudative form is characterised by the presence of subretinal new vessels which leak serum, blood and lipids. Eventually, this exudative process leads to an organised scar tissue and the cica tricial disciform lesion results in significant and permanent loss of central vision.
Clinically, the wide spectrum of the exuda tive form comprises many different and varied patterns including choroidal neovascularisa tion, retinal pigment epithelium detachment and tears, fibrovascular disciform response and even vitreous haemorrhage.
The initial location of the subretinal new vessels (SNV) is probably the most important risk factor and will induce, more or less severe, clinical symptoms.
Previously published randomised control led trials have brought evidence that for patients referred at an early stage there is a beneficial effect on visual outcome from focal laser treatment.
However, less than 20% of patients with new vessels, presenting in referral centres ful fill the criteria of these studies. 2, 3, 4 Most of the patients (58%) present with late stages of the disease process, involving not only the subfoveal area but the entire mac ular area.
Even newly symptomatic patients may have new vessels within the foveal avascular zone by the time they consult an ophthalmologist.
The most important concern is about these subfoveal new vessels ( Fig. 1 ).
They were, until recently, considered not to be amenable to laser treatment: complete obliteration was likely to result in an immedi ate and severe loss of vision. 5 A precise diagnosis and classification system of subretinal neovascularisation in AMD is needed in order accurately to eval uate the natural history and to select appro priate management.
On fluorescein angiography, major types of new vessels are, at present, identifiable:
-visible or well defined SNV (that fill early with dye and leak profusely to the late phase). (Fig. 2a) -occult or poorly defined SNV (that have less precise features on the early frames but give rise to late leakage). (Fig. 2b) -visible SNV can be surrounded or can occur during the natural course, within an area of occult new vessels. (Fig. 2c) -vascularised pigment pigment epithelial detachments can contain either visible or, more frequently, subretinal neovascular membranes (which may be partially obscured by turbid or haemorrhagic fluid). (Fig. 2d) Fluorescein angiography is of major value for the detection and precise location of the neovascular frond in relation to the centre of the foveal avascular zone.
Visible or well-defined neovascularisation fills early with dye, often in a cartwheel pat- tern and leaks profusely in the late phase of the angiogram. (Fig. 1 ) Occult or ill-defined neovascularisation shows an irregular and uneven fluorescence in the early phase. Hyperfluorescent areas alter nate with hypofluorescent areas. Leakage of dye, the hallmark of neovascularisation, is always present and frequently associated with very suggestive hyperfluorescent dots, but precise location is extremely difficult. (Fig.3a,b) The geographic borders of well-defined neovascular membranes can be evaluated during fluorescein angiography, particularly as they relate to the centre of the foveal avas cular zone (the foveola), allowing one to determine and classify subretinal new vessels into four groups:
(1) extrafoveal at more than 400 microns from the foveola, -The possible benefit of krypton laser photocoagulation is presently being evaluated for juxtafoveal subretinal new vessels, located at 1 to 200 microns from the centre of the FAZ.
-None of these studies have included eyes with subfoveal visible new vessels, directly under the anatomic centre of the fovea. Subfoveal new vessels involve at least 50% of the FAZ and will extend to all the FAZ or beyond: new vessels are either emerging directly under the fovea or growing from an extrafoveal position toward the fovea.
It has been shown that 54% of visible new V.A. over a follow-up period of 12 to 25 months. Twenty nine out of 49 eyes (59% ) had a final visual acuity of less than 20/400. Visual acuity was stable in only nine eyes and 23 eyes had lost six lines or more.
-On automatic static perimetry, all but four patients had an increase in size and/or depth of the scotoma with reduced sensitivity.
-Well defined new vessels grew and involved the macular area in 16 out of 25 eyes, associated with haemorrhages and fibrous tis sue in half of the eyes.
-Ill-defined new vessels extended in 13 out of 24 eyes, involving the whole posterior pole in two eyes, and progressed to geo graphic atrophy in two other eyes.
In our long-term natural history study of subfoveal new vessels (2 to 10 years: mean 4 years) ,9
-visible new vessels progressed to a fibro vascular scar in 27 out of 33 eyes, -,-a progressive growth of active new vessels was demonstrated on fluorescein angiography in 51%, during the so-called cicatricial stage.
-significant enlargement of the disciform lesion was usual.
-Occult new vessels, in the same study,9 progressed equally to fibrovascular or to atro phic scars always with residual new vessels and with an enlargement of the macular involvement in most of the cases.
-Vascularised PED showed the worst natural course as most progressed to a large fibrovascular lesion almost always with resi dual new vessels.
Thus, the type of the scars was closely related to the initial type of new vessels and enlargement of the lesion. Only a few cases with a relatively slow and progressive course associated to ill-defined new vessels would result in an atrophic scar with residual vision. The vast majority of eyes deteriorate very severely. For eyes presenting with so-called cicatri cial lesion, it is generally expected that the subfoveal neovascular complex involute and result into a reparative and cicatricial stage, with an elevated fibrovascular or a flat atro phic scar.
However, during our long-term follow-up study, we observed that, the fibrovascular scars remained active in most cases: new vessels were present and the disciform enlarged in half of the eyes.
Even the atrophic scars could enlarge in a comparable proportion. Moreover, geo graphic atrophy may give rise to new-vessels growth, on its margins, as found in 20% of eyes, in our study.
Thus, the results of all the natural history studies clearly demonstrated a poor visual outcome with a progressive and long-term enlargement, haemorrha�es and an increase of the central scotoma.
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Some eyes present with well defined tufts of new vessels within an area of occult new vessels. The natural history suggests that the visual prognosis depends on the well-defined component of the neovascular complex.
Therefore treatment was justified and par tial or total destruction of the subfoveal new vessels resulted.
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Laser treatment approaches are still not clearly defined: partial photocoagulation of the visible new vessels alone does not seem satisfactory; and total laser treatment of both visible and occult new vessels results in exten sive scarring.
The Foveal Photocoagulation Study (in USA) is currently investigating the value of complete laser treatment of these eyes. This treatment could result in a smaller final sco toma size and facilitate the use of low vision aids by preserving more parafoveal retina. Although this study was initiated in February 1986, there are still no data available.
Our treatment approach in Creteil was to occlude the large neovascular membranes with the perifoveal technique. IS Results of a randomised controlled clinical trial will be published soon. In this trial, eyes included had to present with: -Subfoveal involvement due to AMD; -A distance visual acuity equal to or worse than 201100, but not less than 20/100; -Reading vision had to be worse than Jaeger 6.
-The subretinal arcade extended at more than 200 [lm from the centre but less than 2.5 DD wide, without fibrous tissue. (Fig. 5a,b) In order to stop the neovascular growth, confluent and overlapping laser burns were applied to the peripheral neovascular arcade, sparing only the FAZ.
The peripheral neovascular arcade of well defined membranes could be destroyed and resulted in an atrophic scar. The central part of the foveal avascular zone which was avoided, could still exhibit a residual serous detachment, with little leakage. (Fig. 6a,b )
For ill-defined macular new vessels, laser burns were applied to their probable limits but always sparing the FAZ. Here also some central leakage of dye may have existed but which regressed progressively.
Automatic static perimetry was performed before and after treatment. (Fig. 7a,b) The scotoma increased immediately after photo coagulation and remained stable during fol low-up. In 17 eyes, the scotoma was peri-centrally located with a relative central sparing and stable fixation.
The perifoveal treatment has proven bene ficial in treated eyes in preserving distance and near vision (with low vision aids). Statis tical significance was at a p level of 0.01 (dis tance) and 0.03 (n ' ear vision). Complete obliteration of the new vessels and a flat atrophic scar was achieved in 49 out of the 56 treated eyes. Only two observed eyes (out of 49) progressed to an atrophic scar whereas 29 of these 49 eyes resulted in a mac ular disciform lesion. Fig. 7 (a,b) . Automatic static perimetry (b) performed one month after perifoveal laser photocoagulation (a).
In conclusion, the pre-eminence of AMD among blinding diseases is due to the exuda tive form which is the leading cause of severe loss of vision.
Patients rarely present in the referral centres with localised, extrafoveal and well defined new-vessels, amenable to focal laser treatment.
Mostly, they have a diffuse decompensation of retinal pigment epithelium with extensive subretinal neovascularisation and subfoveal new vessels initially or secondarily (due to spontaneous extension or to recurrences after laser treatment).
Natural history studies have shown that subfoveal new vessels are the most severe threat to central vision.
The perifoveal laser pilot study has brought evidence of benefit for preservation of read ing vision with low vision aids, after one year follow-up. This treatment could improve the patient's quality of life.
Since it may, at best, only preserve visual acuity at the level of 20/200, this motivates us to find new approaches for preventive treat ment ... for example, rehabilitation or trans plantation of RPE cells? ...
